Company: INTS
Filing Date: 2025-06-12
Form Type: 424B5
Source: 0001628280-25-031040
Chunk: 10

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-06-12
Form: 424B5
Chunk 10
---
 will be accepted or that if it is, that we will be able to regain compliance with the Stockholders’ Equity Requirement.

Furthermore, as previously reported, on June 6, 2025, we received a separate notice from the Staff indicating that we were not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have a period of 180 calendar days, or until December 3, 2025, to regain compliance with the Bid Price Rule.

We intend to continue to actively monitor the bid price of shares of our common stock and may, if appropriate, consider implementing available options to regain compliance with the Bid Price Rule, which options may include effecting a reverse stock split, if necessary, to attempt to regain compliance. There can be no assurance that we will be able to regain compliance with the Bid Price Rule or will otherwise be in compliance with other Nasdaq Listing Rules, including the Stockholders’ Equity Requirement. Our failure to regain compliance with any Nasdaq Listing Rules could result in delisting.

For more information, please see our Current Reports on Form 8-K, filed with the SEC on each of May 20, 2025 and June 6, 2025, which are incorporated by reference herein as well as “Risk Factors—Risks Related to this Offering and Our Common Stock —We may not satisfy the Nasdaq Capital Market’s requirements for continued listing of our common stock in the future. If we cannot satisfy these requirements, the Nasdaq Capital Market could delist our common stock” in this prospectus supplement.

Implications of Being an Emerging Growth Company and Smaller Reporting Company

As a company with less than $1.235 billion in revenue during our last fiscal year, we qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”) enacted in April 2012.

An “emerging growth company” may take advantage of exemptions from some of the reporting requirements that are otherwise applicable to public companies. These exceptions include:

• being permitted to present only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations;

• not being required to comply with the auditor attestation requirements of Section 404 of the Sarban